CoChat

Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria

Open access

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

The Policy Forum allows health policy makers around the world to discuss challenges

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.0050227

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Simulated Plots of Weekly Incidence Rates and Cumulative Proportions for Recrudescent Primary Infections and Re-Infections Following Treatment of Uncomplicated P. falciparum Malaria with a Slowly Eliminated (Partner) Drug (Half-Life of ~1 Week) The solid line represents recrudescent infections with a cumulative failure rate of 5% by day 42. Dashed lines represent different rates of re-infections corresponding to entomological inoculation rates of two (yellow), four (orange), and six (red) infective mosquito bites/year, respectively. Trailing plasma drug concentrations delay both detectable recrudescent primary and secondary blood stage infections—however, both effects are fading until day 42. Figure 1A illustrates that most recrudescent primary infections are captured by day 42. Extension of follow-up beyond day 28 results in increased ratios of new versus recrudescent infections and hence, elevated risk of outcome misclassifications due to intrinsic limitations of current molecular techniques used to discriminate between primary and secondary infections. The assessment of the total number of recurrent infections as a composite outcome (often denoted the PCR “uncorrected cure rate”) requires some time limits as re-infection occurs eventually in almost everyone after blood concentrations of the drug(s) fall below the MIC (Figure 1B).
Figure 1 Simulated Plots of Weekly Incidence Rates and Cumulative Proportions for Recrudescent Primary Infections and Re-Infections Following Treatment of Uncomplicated P. falciparum Malaria with a Slowly Eliminated (Partner) Drug (Half-Life of ~1 Week) The solid line represents recrudescent infections with a cumulative failure rate of 5% by day 42. Dashed lines represent different rates of re-infections corresponding to entomological inoculation rates of two (yellow), four (orange), and six (red) infective mosquito bites/year, respectively. Trailing plasma drug concentrations delay both detectable recrudescent primary and secondary blood stage infections—however, both effects are fading until day 42. Figure 1A illustrates that most recrudescent primary infections are captured by day 42. Extension of follow-up beyond day 28 results in increased ratios of new versus recrudescent infections and hence, elevated risk of outcome misclassifications due to intrinsic limitations of current molecular techniques used to discriminate between primary and secondary infections. The assessment of the total number of recurrent infections as a composite outcome (often denoted the PCR “uncorrected cure rate”) requires some time limits as re-infection occurs eventually in almost everyone after blood concentrations of the drug(s) fall below the MIC (Figure 1B).CC BY · PubMed Central
Figure 2 Simplified Outline of the Iterative Process of the Clinical Development of New Antimalarial Candidate Drugs or Drug Combinations Phase III trials are designed to provide pivotal efficacy and safety data for obtaining regulatory approval. The indicated numbers of study participants are approximations of the magnitude of required total sample sizes in different transmission settings.
Figure 2 Simplified Outline of the Iterative Process of the Clinical Development of New Antimalarial Candidate Drugs or Drug Combinations Phase III trials are designed to provide pivotal efficacy and safety data for obtaining regulatory approval. The indicated numbers of study participants are approximations of the magnitude of required total sample sizes in different transmission settings.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 46

  1. Snow, 2005, Nature, 434, 214
  2. Marsh, 1995, N Engl J Med, 332, 1399
  3. Snow, 2002, Adv Parasitol, 52, 235
  4. Snow, 2001, Trends Parasitol, 17, 593
  5. Snow, 2003, Trends Parasitol, 19, 363
  6. Mutabingwa, 2005, Acta Trop, 95, 305
  7. Bathurst, 2006, Trends Parasitol, 22, 301
  8. Amin, 2007, Malar J, 6, 72
  9. Stepniewska, 2006, Malar J, 5, 127
  10. Kamya, 2007, PLoS Clin Trials, 2, e20
  11. Staedke, 2004, Lancet, 364, 1950
  12. Uhlemann, 2007, J Infect Dis, 195, 134
  13. Bhattarai, 2007, PLoS Med, 4, e309
  14. Laufer, 2007, Am J Trop Med Hyg, 77, 160
  15. Borrmann, 2008, Antimicrob Agents Chemother, 52, 1799
  16. Piola, 2005, Lancet, 365, 1467
  17. Price, 2007, Malar J, 6, 119
  18. Barnes, 2008, Trends Parasitol, 24, 127
  19. White, 1997, Antimicrob Agents Chemother, 41, 1413
  20. Djimde, 2003, Am J Trop Med Hyg, 69, 558
  21. Stepniewska, 2004, Antimicrob Agents Chemother, 48, 4271
  22. Price, 2006, Clin Infect Dis, 42, 1570
  23. Epstein, 2007, J Infect Dis, 196, 145
  24. Guthmann, 2006, Antimicrob Agents Chemother, 50, 3734
  25. Lee, 2006, J Infect Dis, 193, 1160
  26. Slater, 2005, Am J Trop Med Hyg, 73, 256
  27. Gatton, 2008, Trends Parasitol, 24, 68
  28. Collins, 2006, Malar J, 5, 122
  29. Farnert, 2001, Trans R Soc Trop Med Hyg, 95, 225
  30. Imwong, 2007, J Infect Dis, 195, 927
  31. White, 2008, Malar J, 7, 9
  32. Olliaro, 2008, Trop Med Int Health, 13, 83
  33. Smith, 1994, Stat Med, 13, 2345
  34. Staedke, 2001, Lancet, 358, 368
  35. Zongo, 2007, Lancet, 369, 491
  36. Greenhouse, 2007, Antimicrob Agents Chemother, 51, 3096
  37. Nwaka, 2006, Nat Rev Drug Discov, 5, 941
  38. Ratcliff, 2007, Lancet, 369, 757
  39. Tarning, 2005, Antimicrob Agents Chemother, 49, 5127
  40. Schulz, 2002, Lancet, 359, 515
  41. Myint, 2004, Trans R Soc Trop Med Hyg, 98, 73
  42. Jones, 1996, BMJ, 313, 36
  43. Piaggio, 2006, JAMA, 295, 1152
  44. Machekano, 2008, Stat Methods Med Res, 17, 191
  45. Rothmann, 2003, Stat Med, 22, 239
  46. Price, 2007, Antimicrob Agents Chemother, 51, 4090

Cited by

See all 15

Metadata

Authors
Borrmann, S., Peto, T., Snow, R. W., Gutteridge, W., & White, N. J.
Affiliations
  • Kenya Medical Research Institute (KE)
  • Heidelberg University (DE)
Corresponding author
Borrmann, Steffen
Venue
PLoS Medicine
Published
2008-11-18
Volume
5
Issue
11
Pages
e227
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2026681785
Cited by
15
References
49
Citations by year
2022: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 1 · 2014: 1 · 2012: 1
FWCI
2.31
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
  • Wellcome Trust (079080)
  • Deutsche Forschungsgemeinschaft (SFB 544, A7, SFB544)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
Keywords
antimalarial drugs, trial design, uncomplicated malaria, Plasmodium falciparum, malaria treatment efficacy, health policy
MeSH terms
Animals, Antimalarials, Drug Therapy, Combination, Humans, Plasmodium falciparum, Survival Analysis, Malaria, Falciparum, Treatment Outcome, Clinical Trials, Phase III as Topic, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.